Multiple Myeloma

Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma

Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...

Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma

Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and...

FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma

The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly...
On location

Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma

Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
On location

Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...

A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...

Cardiovascular Events Common With Proteasome Inhibitor Therapy for Previously Treated Multiple Myeloma

Cardiovascular adverse events (CVAEs) commonly occur during proteasome inhibitor (PI) therapy for relapsed/refractory multiple myeloma (MM), particularly in patients with elevated natriuretic peptides or...
On location

Can Immunomodulatory Drugs Overcome CHIP’s Effects in Post-Transplant Multiple Myeloma?

Patients with multiple myeloma (MM) who harbor somatic mutations in hematopoietic cells, known as clonal hematopoiesis of indeterminate potential (CHIP), have better post–autologous hematopoietic...

More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma

As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

European Commission Approves Elotuzumab Triplet for Multiple Myeloma

The European Commission (EC) has approved elotuzumab plus pomalidomide and low-dose dexamethasone (EPd) to treat relapsed and refractory multiple myeloma in adult patients who...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.